Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating reaffirmed by stock analysts at Piper Sandler in a report issued on Friday,Benzinga reports. They presently have a $58.00 price objective on the biotechnology company’s stock, up from their prior price objective of $45.00. Piper Sandler’s price target would indicate a potential upside of 87.12% from the company’s current price.

Several other equities analysts have also issued reports on the company. iA Financial set a $48.00 target price on Capricor Therapeutics in a research note on Wednesday, December 3rd. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday. UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a report on Monday, December 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.91.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $2.42 during midday trading on Friday, reaching $31.00. 1,598,876 shares of the stock were exchanged, compared to its average volume of 1,333,494. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The stock has a market capitalization of $1.71 billion, a P/E ratio of -17.19 and a beta of 0.37. The company has a 50 day simple moving average of $25.66 and a 200 day simple moving average of $16.35.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, research analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CAPR. ACT Capital Management LLC purchased a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $43,000. GoalVest Advisory LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $59,000. Allworth Financial LP lifted its holdings in shares of Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 3,264 shares during the period. Farther Finance Advisors LLC acquired a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $28,000. Finally, State of Wyoming boosted its stake in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 1,913 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of deramiocel and set an August decision window, reviving the pathway for approval and reducing some regulatory uncertainty. Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
• Positive Sentiment: Late-breaking HOPE-3 Phase 3 data presented at the 2026 MDA conference showed significant functional benefits for deramiocel in Duchenne muscular dystrophy — a clinical readout that supports the therapy’s commercial potential if approved. HOPE-3 Data Press Release
• Positive Sentiment: HC Wainwright reiterated a Buy rating on CAPR, which can provide support from buy-side interest and signal confidence to some investors. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Neutral Sentiment: Company filed its fourth-quarter and full-year 2025 results and provided a corporate update; the release contains financial details and operational commentary investors will parse for runway and milestones. Q4 & Full-Year 2025 Results
• Neutral Sentiment: Q4 2025 earnings call transcript and supplemental materials are available for detailed management commentary and Q&A — useful for assessing guidance, cash runway and commercialization planning. Earnings Call Transcript
• Neutral Sentiment: News outlets flagged “earnings on deck” coverage following the FDA review resumption — media attention can amplify both upside and downside moves depending on follow-up items. Investing.com Coverage
• Neutral Sentiment: Recent short-interest reports show anomalous “0 shares” figures and a 0.0 days-to-cover metric — likely data noise rather than a material shift in short positioning. (Multiple short-interest updates posted March 11–12.)
• Negative Sentiment: Q4 EPS missed consensus: CAPR reported a loss of ($0.62) vs. analysts’ ($0.51) estimate. An EPS miss amid a biotech story often triggers immediate selling as investors re-price near-term execution and funding risk. MarketBeat Earnings Coverage

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.